TRCT
APGN

Tower Research Capital (TRC)’s Apexigen, Inc. Common Stock APGN Stock Holding History

Tower Research Capital (TRC)’s Portfolio APGN Stock Details APGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,106
Closed -$5.21K – 6425
2023
Q2 		$5.21K Buy
12,106
+348
+3% +$165 ﹤0.01% 4847
2023
Q1 		$6K Buy
11,758
+1,450
+14% +$1.74K ﹤0.01% 4915
2022
Q4 		$7K Buy
10,308
+10,191
+8,710% +$19.9K ﹤0.01% 4655
2022
Q3 		$0 Buy
+117
New +$952 ﹤0.01% 6745
2022
Q2 		– Sell
-151
Closed -$2K – 6785
2022
Q1 		$2K Sell
151
-100
-40% -$1K ﹤0.01% 5660
2021
Q4 		$3K Buy
251
+79
+46% +$787 ﹤0.01% 5539
2021
Q3 		$2K Buy
172
+118
+219% +$1.17K ﹤0.01% 5341
2021
Q2 		$1K Buy
+54
New +$535 ﹤0.01% 5303

Tower Research Capital (TRC)'s APGN Position: Q3 2023 in Review

Tower Research Capital (TRC) sold out of Apexigen, Inc. Common Stock (APGN) in Q3 2023, closing a stake of 12,106 shares — an estimated $5.21K sold.

Tower Research Capital (TRC) first reported a position in APGN in Q2 2021 and held it in 8 quarters. The position peaked at $7K in Q4 2022. 0 funds tracked by Wall St. Rank hold APGN as of Q3 2023.

  • Tower Research Capital (TRC) reported no remaining Apexigen, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 12,106 Apexigen, Inc. Common Stock shares in Q3 2023, an estimated $5.21K.
  • Tower Research Capital (TRC) first reported a position in Apexigen, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
  • Tower Research Capital (TRC)'s Apexigen, Inc. Common Stock position peaked at $7K in Q4 2022.
  • 0 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q3 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2023, filed 14 Nov 2023.